Access the Akari CEO Corner here BOSTON and LONDON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), today announced the next CEO Corner segment has been published on the Company’s website. For this CEO Corner segment, Abizer Gaslightwala, CEO of Akari, provides an overview of the Company’s innovation in ADCs, highlighting its novel PH1 payload and its dual mechanism of action. Additiona ...

Core Insights - The novel spliceosome targeting payload, PH1, shows potential in inducing cancer cell cytotoxicity and activating anti-tumor immunity through various mechanisms [1][3] - The combination of Trastuzumab-PH1 ADC with anti-PD1 therapy significantly outperforms Kadcyla® with anti-PD1 in achieving complete tumor regressions (74% vs. 42%, p<0.05) [1][12] - Akari Therapeutics is advancing its lead ADC candidate, AKTX-101, which targets the Trop2 receptor and utilizes the PH1 payload, aiming to enter clinical trials soon [7][9] Company Overview - Akari Therapeutics is focused on developing next-generation spliceosome payload antibody drug conjugates (ADCs) [9] - The company’s innovative ADC platform allows for the generation and optimization of ADC candidates tailored to specific targets [9] - The PH1 payload is designed to disrupt RNA splicing in cancer cells, leading to cancer cell death and immune activation [9] Mechanism of Action - Trastuzumab-PH1 induces RNA mis-splicing, resulting in increased neoantigen generation and a subsequent rise in anti-cancer immune cells within the tumor microenvironment [4][12] - The combination therapy enhances immune responses, including the polarization of macrophages, increase in neutrophils, and expansion of B cell clones producing IgM antibodies [3][12] - The synergy between Trastuzumab PH1 and anti-PD1 therapy is attributed to their complementary effects on the immune system, particularly the expansion of gamma-delta T cell clones [3][12] Market Potential - The immuno-oncology therapeutic class is currently valued at approximately $50 billion per year, with the potential for significant growth through innovative therapies like those developed by Akari [1][4] - The unique results from the Trastuzumab-PH1 and anti-PD1 combination therapy could establish a new standard of care in cancer treatment, improving patient outcomes [6][12] Upcoming Events - Akari Therapeutics will host a live webcast on November 18, 2025, to discuss the presented data, providing insights for investors and analysts [1][8]

Core Insights - Akari Therapeutics is presenting data on its novel antibody drug conjugate (ADC) payload, PH1, at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting, highlighting its immune mechanism-of-action and potential in oncology [1][2] Company Overview - Akari Therapeutics is focused on developing next-generation spliceosome payload ADCs, with its lead candidate, AKTX-101, targeting the Trop2 receptor on cancer cells [5][6] - The PH1 payload is designed to disrupt RNA splicing within cancer cells, showing preclinical efficacy in inducing cancer cell death and activating immune cells [5][6] Research Findings - The abstract presented at SITC indicates that the PH1 ADC, in combination with anti-PD-1, resulted in a higher rate of complete tumor regressions compared to a first-in-class ADC with a microtubule inhibitor payload [2] - The immune response stimulated by the PH1 ADC is attributed to neoantigen activation, which enhances the activity of antigen-presenting cells, B, and T-cells [2] - Notably, the combination of PH1 ADC and anti-PD-1 expanded the population of gamma-delta T cells, which are effective in tumor killing [2] Presentation Details - The oral and poster presentations will take place on November 7 and 9, 2025, at the Gaylord National Resort and Convention Center, with specific times and locations provided for attendees [3][4]

Core Insights - Akari Therapeutics is presenting new data on its novel antibody drug conjugate (ADC) payload, PH1, at the 40th Annual SITC Meeting, highlighting its immune mechanism-of-action and potential in oncology treatment [1][2]. Company Overview - Akari Therapeutics is focused on developing next-generation spliceosome payload ADCs, with its lead candidate, AKTX-101, targeting the Trop2 receptor on cancer cells [5]. - The PH1 payload is a spliceosome modulator designed to disrupt RNA splicing in cancer cells, showing preclinical efficacy in inducing cancer cell death and activating immune responses [5]. Research Findings - The abstract presented at SITC indicates that the PH1 ADC, in combination with anti-PD-1, resulted in a higher rate of complete tumor regressions compared to a first-in-class ADC with a microtubule inhibitor payload [2]. - The immune response stimulated by the PH1 ADC involves neoantigen activation, antigen-presenting cells, and T-cell activation, leading to enhanced therapeutic potential [2]. Presentation Details - The oral and poster presentations will provide further insights into the findings, with specific sessions scheduled for November 7 and November 9, 2025 [3][4].

Core Insights - Akari Therapeutics has launched a new platform called CEO Corner, aimed at providing deeper insights into the company's press releases, corporate developments, and pipeline progress [2][3] - The CEO Corner will allow stakeholders to ask questions and suggest topics for future discussions, enhancing engagement and transparency [1][2] Company Overview - Akari Therapeutics is focused on developing next-generation spliceosome payload antibody drug conjugates (ADCs) for oncology applications [4] - The company's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and utilizes a proprietary linker to deliver a novel PH1 payload directly into tumors [4] - PH1 is designed to modulate RNA splicing within cancer cells, leading to cancer cell death and activation of immune responses, showing significant activity in preclinical studies compared to traditional ADCs [4] Product Development - AKTX-101 has demonstrated prolonged survival in preclinical models, both as a single agent and in combination with checkpoint inhibitors, indicating its potential for synergistic effects [4] - The company is actively generating validating data on the PH1 payload to further advance AKTX-101 and explore other undisclosed targets [4]

Core Points - Akari Therapeutics has entered into a definitive agreement for the issuance and sale of 3,125,000 American Depositary Shares (ADSs) at a price of $0.80 per ADS in a registered direct offering [1] - The gross proceeds from the offering are expected to be approximately $2.5 million, which will be used for working capital, general corporate purposes, and continued research and development [4] Offering Details - Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the offering [2] - The company will also issue unregistered Series E and Series F Warrants to purchase up to 3,125,000 ADSs at an exercise price of $0.98 per share [3] - The offering is expected to close on or about October 16, 2025, subject to customary closing conditions [3] Research and Development Focus - The funds from the offering will be used to generate differentiated data on the novel ADC payload, which targets cancer cells and aims to highlight its unique action against cancer [4] - Akari's lead candidate, AKTX-101, utilizes a novel spliceosome modulator payload designed to disrupt RNA splicing within cancer cells, showing significant activity in preclinical studies [8][9] Company Overview - Akari Therapeutics is focused on developing next-generation spliceosome payload antibody drug conjugates (ADCs) [8] - The company aims to advance its lead asset, AKTX-101, and other undisclosed targets with its novel payload [9]

Core Insights - Akari Therapeutics has filed two new provisional patent applications with the USPTO, focusing on its novel immuno-oncology payload PH1 and its combination therapy with other immuno-oncology drugs [1][2][3] Patent Applications - The first patent application protects Akari's novel immuno-oncology payload PH1, which is a Thailanstatin analog, and its mechanism of action that activates the host immune system against cancer [1] - The second application covers a combination therapy of PH1 ADCs with other immuno-oncology drugs that alleviate checkpoint inhibition, demonstrating synergy in preclinical models [1][3] Strategic Goals - The patent filings are part of Akari's strategy to establish a new class of immuno-oncology ADC therapies, building on the success of checkpoint inhibitors [2] - The company aims to enhance its intellectual property estate to create long-term value for itself and potential partners [2] Clinical Implications - Akari's data suggest the potential for a new ADC paradigm targeting cancer through spliceosome modulation, which could improve clinical outcomes compared to existing therapies [4] - Checkpoint inhibitors currently benefit only 20-30% of patients, indicating a significant opportunity for Akari's innovative approach [4] Pipeline Development - Akari is expanding its ADC pipeline to include multiple targets, such as AKTX-101 (Trop2 ADC with PH1 payload) and future programs like AKTX-102 [5][6] - The lead candidate AKTX-101 has shown significant activity and prolonged survival in preclinical studies, with potential synergy with checkpoint inhibitors [6]

Core Insights - Akari Therapeutics has announced promising preclinical data for its novel antibody drug conjugate (ADC) payload, PH1, which targets the AR-V7 receptor linked to hormone refractory prostate cancer progression [1][2][3] Group 1: Product Development - PH1 has shown the ability to suppress AR-V7 receptor expression in a hormone-refractory metastatic castration resistant prostate cancer (mCRPC) model, indicating its potential effectiveness where current therapies fail [3] - In hormone-sensitive LnCAP cells, PH1 demonstrated single-agent benefits and additive effects when combined with existing therapies like Xtandi and Erleada, suggesting potential for first-line combination regimens [4] - The company aims to develop PH1 ADCs as either first-line therapies with ARPIs or second-line therapies for patients who have failed ARPI treatments [5] Group 2: Market Context - There is a significant unmet need for effective therapies in ARPI-resistant hormone refractory prostate cancer, as current options are limited primarily to traditional chemotherapy [2] - Current first-line therapies, including enzalutamide (Xtandi), apalutamide (Erleada), and darolutamide (Nubeqa), have substantial annual sales, indicating a lucrative market for effective alternatives [2] Group 3: Company Overview - Akari Therapeutics specializes in developing next-generation spliceosome payload ADCs, with its lead candidate, AKTX-101, targeting the Trop2 receptor and utilizing a novel PH1 payload [6] - The company’s innovative ADC discovery platform allows for the generation and optimization of ADC candidates tailored to specific targets, enhancing its competitive edge in oncology [6][7]

Core Insights - Akari Therapeutics has filed a provisional patent application for its antibody drug conjugate (ADC) platform utilizing the spliceosome payload PH1 for cancer treatment, aiming to enhance its proprietary position in the oncology sector [1][2][4] Company Developments - The provisional patent application expands Akari's intellectual property estate and is based on the advances in understanding spliceosome modulation, which could lead to differentiated clinical outcomes for cancer patients [2][4] - Akari's lead candidate, AKTX-101, targets the Trop2 receptor and utilizes the PH1 payload, which is designed to disrupt RNA splicing in cancer cells, showing significant activity and prolonged survival in preclinical studies compared to traditional ADCs [5] Industry Context - Alternative splicing (AS) is a process that cancer cells exploit to produce protein isoforms that support tumor growth and survival, making it a critical target for cancer therapies [3] - Disrupting AS is seen as a fundamental approach to targeting various cancers, including those driven by specific spliced variants, thus positioning Akari to potentially lead in developing therapies against a wide range of cancers [3]

Company Overview - Akari Therapeutics is an oncology biotechnology company focused on developing next-generation spliceosome payload antibody drug conjugates (ADCs) [4] - The company utilizes an innovative ADC discovery platform to generate and optimize ADC candidates for various targets [4] Lead Product Candidate - Akari's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and employs a proprietary linker to deliver a novel PH1 payload directly into tumors [4] - PH1 is a spliceosome modulator designed to disrupt RNA splicing within cancer cells, leading to cancer cell death and activation of immune cells [4] - Preclinical studies indicate that AKTX-101 has significant activity and prolonged survival compared to traditional ADCs, and it shows potential synergy with checkpoint inhibitors [4] Upcoming Events - Abizer Gaslightwala, President and CEO of Akari Therapeutics, will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025 [1] - Management will also be available for in-person one-on-one meetings with qualified investors during the conference [2] - A video webcast of the presentation will be available on-demand starting September 5, 2025, and will be archived for 90 days [3]